Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with no effective standard therapy. Breast cancer stem-like cells (BCSCs) in primary TNBCs are reported to be responsible for metastatic spread of the disease and resistance to chemotherapy, but no availabl...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Ly, Stanley, Anand, Vivek, El-Dana, Fouad, Nguyen, Khoa, Cai, Yiming, Cai, Shirong, Piwnica-Worms, Helen, Tripathy, Debasish, Sahin, Aysegul A, Andreeff, Michael, Battula, Venkata Lokesh
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2021
Aiheet:
Clinical/Translational Cancer Immunotherapy
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970220/
https://ncbi.nlm.nih.gov/pubmed/33722905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001197
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia